

The 7th Engadin Prostate Cancer Winter Symposium

Zuoz 15. – 17. March 2012

www.engadin-symposium.ch

SCREENING

pro and contra

THERAPY



The 7th Engadin Prostate Cancer Winter Symposium Zuoz 15. – 17. March 2012

Dear colleagues and friends of this meeting,

Time flows by quickly and after two years we have the pleasure to invite you for the 7th time to our Engadin Prostate Cancer Winter Symposium.

While a number of developments in early diagnosis and local treatment are emerging and new trials results has become available, the important questions remain: How to inform about prostate cancer risk and how to treat the individual patient? Is active surveillance a justifiable option? How to deal with high risk PCa and with recurrent disease if primary treatment fails?

We will discuss these topics in a pro and contra form to give recommendations for the every day practice. We intend to have a high quality scientific meeting in a special relaxing atmosphere, facilitating open and profound discussions. We will be very glad to hear your contributions to the relevant topics.

On this occasion I would like to thank Dr. Maciej Kwiatkowski and Prof. Tullio Sulser for support and collaboration in preparation to this symposium. I want also to acknowledge the support of the Prostate Cancer Research Foundation.

I am looking forward to see you in Zuoz

With best regards



Franz Recker

PRELIMINARY PROGRAM

PCa screening trials in perspective

Jonas Hugosson, Göteborg and Gerald Andriole, St. Louis, MO

Recommendation of the US Preventive Services Task Force

Peter Albertsen, Farmington, CT (pro) and Franz Recker, Aarau (contra)

Screening: when to stop? Comorbidity and age in decision making

Peter Albertsen, Farmington, CT

Intelligent use of PSA in the year 2012

Alexandre Zlotta, Toronto

PET/MRI in PCa imaging

Christophe Iselin, Geneva

Learning curve in prostate MRI

Jelle Barentsz, Nijmegen

Recent developments in TRUS imaging

Klaus-Peter Jünemann, Kiel (histoscanning) and Peter Hammerer, Braunschweig (elastography)

Active surveillance: pro and contra

Laurence Klotz, Toronto (pro) and Markus Graefen, Hamburg (contra): the 2nd round

Trigger points for starting therapy in the active surveillance

Laurence Klotz, Toronto

30 years of radical prostatectomy: where do we stand?

Hartwig Huland, Hamburg

Quality assurance in RP: a plea to establish expanded pathological criteria of surgical resection

Christian Barre, Nantes (open), Tullio Sulser, Zürich (robotic)

Microscopic intraoperative imaging

Guido Sauter, Hamburg

Extended and salvage lymphadenectomy in treatment of PCa

Klaus-Peter Jünemann, Kiel

Histological markers of prostate cancer

Rainer Grobholz, Aarau

External beam radiation: what have changed in the last 30 years?

Thomas Wiegel, Ulm

LDR-brachytherapy for PCa

Hans-Peter Schmid, St. Gallen

Biochemical recurrence: what does it mean?

Markus Graefen, Hamburg

S3 guideline for PCa

Manfred Wirth, Dresden

Technics for continence repair after RP

Margrit Fisch, Hamburg

Tissue selective therapies for PCa

Mark Emberton

Secondary erectile dysfunction – prevention and treatment

Herbert Sperling, Mönchengladbach

Timing of hormonal therapy: Immediate / continuous vs. delayed / intermittent hormonal ablation in advanced PCa

Manfred Wirth, Dresden (immediate) and Kurt Miller, Berlin (intermittent): the 2nd round

Maintaining bone health in PCa

George Thalman, Berne

Hormonal refractory PCa (HRPCa). What are the options?

“State of the art” vs. new treatment regimens
Silke Gillesen, St. Gallen, Richard Cathomas, Chur, Peter Hammerer, Braunschweig

Chemoprevention and role of nutrition in PCa

Gerald Andriole, St. Louis (MO)

New radionuclide treatment options in PCa

Kurt Miller, Berlin

GENERAL INFORMATION

Official language: English

Abstracts deadline: 31st of January, 2012

Symposium Venue: Lyceum Alpinum Zuoz

Scientific meeting schedule:

Thursday, 15. March beginning at 13.00 (official meeting start)

Friday, 16. March beginning at 8.30

Saturday, 17. March beginning at 8.00

This Symposium earns 20 CME points of SGU and DGU (Swiss and German Urological Association)

Social Evening: Saturday, 17. March beginning at 19.00

Optional (for early guests): "Coming together" on 14. March at 18.30

REGISTRATION FEES AND PAYMENT

Participant: 460.– CHF (560.– CHF after January 20, 2012)
(including social evening)

Accompanying person: 250.– CHF (including social evening)

Cancellation fees: 100.– CHF (230.– CHF after January 20, 2012, no fee refund after February 15, 2010)

Payment by bank transfer to:

Prostate Cancer Symposium, Bank account No. 770526-91

IBAN: CH65 0588 1077 0526 9100 0 SWIFT/BIC: AHHBCH22XXX

Bank relation: Neue Aargauer Bank, 5001 Aarau, Switzerland

You can preferably register and book your hotel via Symposium website:
www.engadin-symposium.ch

All inquiries and abstracts are to be directed to:

Dr. M. Kwiatkowski, Department of Urology
Kantonsspital Aarau, CH-5001 Aarau, Switzerland

E-mail: info@engadin-symposium.ch

Tel.: +41 62 838 47 47

Fax: +41 62 838 47 53

SYMPOSIUM VENUE:

Lyceum Alpinum Zuoz

ACCOMODATION:

Castell Zuoz, Alpenschloss Hotel, CH-7524 Zuoz

Tel. +41 81 851 52 53, Fax +41 81 851 52 54

www.hotelcastell.ch

Posthotel Engiadina, CH-7524 Zuoz

Tel. +41 81 854 10 21, Fax +41 81 854 33 03

www.hotelengiadina.ch

Hotel Klarer, CH-7524 Zuoz

Tel. +41 81 851 34 34, Fax +41 81 851 34 00

www.klarerconda.ch

Hotel Crusch Alva, CH-7524 Zuoz

Tel. +41 81 854 13 19, Fax +41 81 854 24 59

www.hotelcruschalva.ch



You are advised to make your hotel reservation as soon as possible, because of the high winter season. A limited number of rooms at reduced prices for congress participants could be arranged (first come first served basis). This contingent can be kept only until the 31st of January 2012.

See registration and accomodation form for details.

You can reach Zuoz / St. Moritz by railway (SBB):

Zürich - Landquart - Zuoz

